NovoCure Limited (NVCR)
(Delayed Data from NSDQ)
$22.15 USD
-0.98 (-4.24%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $22.17 +0.02 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum C VGM
Brokerage Reports
0 items in cart
NovoCure Limited [NVCR]
Reports for Purchase
Showing records 141 - 160 ( 211 total )
Company: NovoCure Limited
Industry: Medical Services
Sales and Reimbursement Traction should Accelerate Path to Profitability
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: NovoCure Limited
Industry: Medical Services
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: NovoCure Limited
Industry: Medical Services
Moving up Ramp on Strong Start to Year, Expanding into Mesothelioma
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: NovoCure Limited
Industry: Medical Services
Mesothelioma Success Highlights Potential New Indications
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: NovoCure Limited
Industry: Medical Services
NCCN Elevates Optune plus Temozolomide to Category 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: NovoCure Limited
Industry: Medical Services
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
Looking for Progress in International Markets and Reimbursement Front in 2018
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: NovoCure Limited
Industry: Medical Services
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
Company: NovoCure Limited
Industry: Medical Services
Optune Receives Reimbursement in Japan--an Important Growth Driver
Provider: WEDBUSH SECURITIES INC.
Company: NovoCure Limited
Industry: Medical Services
High Compliance with Optune Results in Impressive 5-yr Survival Rate of 29%
Provider: WEDBUSH SECURITIES INC.
Company: NovoCure Limited
Industry: Medical Services
FASB 606 To Simplify NVCR''s Revenue Recognition; Adjusting GAAP Revenue Higher
Provider: WEDBUSH SECURITIES INC.
Company: NovoCure Limited
Industry: Medical Services
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: NovoCure Limited
Industry: Medical Services
Solid Qtr Driven by Adoption and Operating Leverage
Provider: WEDBUSH SECURITIES INC.
Company: NovoCure Limited
Industry: Medical Services
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: NovoCure Limited
Industry: Medical Services
Medical Devices - 3Q17 Earnings Preview: Anti-climatic due to Seasonally Soft Qtr and Hurricanes
Provider: WEDBUSH SECURITIES INC.